Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Postmarketing Study Evaluating the Effectiveness and Safety of the XEN45 Glaucoma Treatment System in Subjects With Open-Angle Glaucoma in China

NCT05821855 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT05821855
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05821855 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Postmarketing Study Evaluating the Effectiveness and Safety of the XEN45 Glaucoma Treatment System in Subjects With Open-Angle Glaucoma in China
Lead sponsor
AbbVie
Phase
Phase 4
Overall status
Active, not recruiting
Start date
January 9, 2024
Completion date
July 31, 2030
Enrollment
120 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

oag, open-angle glaucoma